IL290276B2 - Tetracyclic Compound, Preparation Method and Use Thereof - Google Patents
Tetracyclic Compound, Preparation Method and Use ThereofInfo
- Publication number
- IL290276B2 IL290276B2 IL290276A IL29027622A IL290276B2 IL 290276 B2 IL290276 B2 IL 290276B2 IL 290276 A IL290276 A IL 290276A IL 29027622 A IL29027622 A IL 29027622A IL 290276 B2 IL290276 B2 IL 290276B2
- Authority
- IL
- Israel
- Prior art keywords
- preparation
- tetracyclic compound
- tetracyclic
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910712388 | 2019-08-02 | ||
| CN201910899724 | 2019-09-23 | ||
| CN201911157922 | 2019-11-22 | ||
| CN202010054185 | 2020-01-17 | ||
| PCT/CN2020/106573 WO2021023154A1 (en) | 2019-08-02 | 2020-08-03 | Tetracyclic compound, preparation method therefor and use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL290276A IL290276A (en) | 2022-04-01 |
| IL290276B1 IL290276B1 (en) | 2026-01-01 |
| IL290276B2 true IL290276B2 (en) | 2026-05-01 |
Family
ID=74483410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL290276A IL290276B2 (en) | 2019-08-02 | 2020-08-03 | Tetracyclic Compound, Preparation Method and Use Thereof |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220298174A1 (en) |
| EP (1) | EP4011886A4 (en) |
| JP (1) | JP7756069B6 (en) |
| KR (1) | KR20220079521A (en) |
| CN (1) | CN112300195B (en) |
| AU (1) | AU2020325477A1 (en) |
| CA (1) | CA3149403A1 (en) |
| IL (1) | IL290276B2 (en) |
| MX (1) | MX2022001421A (en) |
| WO (1) | WO2021023154A1 (en) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| ES3004338T3 (en) | 2018-09-10 | 2025-03-12 | Mirati Therapeutics Inc | Combination therapies |
| WO2020055761A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| JP2022500385A (en) | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス， インコーポレイテッド | Combination therapy |
| KR102871791B1 (en) | 2018-09-10 | 2025-10-15 | 미라티 테라퓨틱스, 인크. | combination therapy |
| TWI831855B (en) | 2018-10-26 | 2024-02-11 | 日商大鵬藥品工業股份有限公司 | Novel indazole compounds or salts thereof |
| CA3112129A1 (en) | 2018-12-05 | 2020-06-11 | Mirati Therapeutics, Inc. | Combination therapies |
| JP7592601B2 (en) | 2019-01-10 | 2024-12-02 | ミラティ セラピューティクス， インコーポレイテッド | KRAS G12C inhibitors |
| CN112390818B (en) * | 2019-08-12 | 2023-08-22 | 劲方医药科技(上海)有限公司 | Substituted heteroaromatic ring dihydropyrimidinone derivatives, its preparation method and medical application |
| CA3148745A1 (en) | 2019-08-29 | 2021-03-04 | Xiaolun Wang | Kras g12d inhibitors |
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| CN114761012B (en) | 2019-09-24 | 2025-03-21 | 米拉蒂治疗股份有限公司 | Combination therapy |
| CA3158793A1 (en) | 2019-10-28 | 2021-05-06 | Merck Sharp & Dohme Corp. | Small molecule inhibitors of kras g12c mutant |
| WO2021106230A1 (en) | 2019-11-29 | 2021-06-03 | 大鵬薬品工業株式会社 | Novel phenol compound or salt thereof |
| KR20220130126A (en) | 2019-12-20 | 2022-09-26 | 미라티 테라퓨틱스, 인크. | SOS1 inhibitor |
| CN113929676A (en) * | 2020-07-14 | 2022-01-14 | 浙江海正药业股份有限公司 | Pyridino-heterocyclic derivative and preparation method and application thereof |
| CN113980032B (en) * | 2020-07-27 | 2023-06-16 | 江苏恒瑞医药股份有限公司 | Fused tetracyclic derivative, preparation method thereof and application thereof in medicines |
| US12286431B2 (en) | 2020-09-11 | 2025-04-29 | Mirati Therapeutics, Inc. | Crystalline forms of a KRas G12C inhibitor |
| US12398154B2 (en) | 2020-12-15 | 2025-08-26 | Mirati Therapeutics, Inc. | Azaquinazoline pan-KRas inhibitors |
| EP4262803A4 (en) | 2020-12-16 | 2025-03-12 | Mirati Therapeutics, Inc. | PAN-KRAS TETRAHYDROPYRIDOPYRIMIDINE INHIBITORS |
| CN114716435A (en) * | 2021-01-04 | 2022-07-08 | 广州百霆医药科技有限公司 | KRAS G12C mutation inhibitor |
| WO2022188729A1 (en) * | 2021-03-07 | 2022-09-15 | Jacobio Pharmaceuticals Co., Ltd. | Fused ring derivatives useful as kras g12d inhibitors |
| EP4373827A4 (en) * | 2021-07-23 | 2025-06-04 | Suzhou Zanrong Pharma Limited | KRAS G12D INHIBITORS AND THEIR USES |
| EP4395769A1 (en) | 2021-09-01 | 2024-07-10 | Novartis AG | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
| EP4408851A4 (en) * | 2021-09-27 | 2025-09-17 | Jacobio Pharmaceuticals Co Ltd | POLYCYCLIC FUSED RING DERIVATIVES AND THEIR USE |
| WO2023066371A1 (en) * | 2021-10-22 | 2023-04-27 | 江苏恒瑞医药股份有限公司 | Nitrogen-containing tetracyclic compound, preparation method therefor, and medical use thereof |
| TW202325298A (en) * | 2021-11-01 | 2023-07-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | A nitrogen-containing tetracyclic compound, a preparation method and medical use thereof |
| WO2023103906A1 (en) * | 2021-12-07 | 2023-06-15 | 贝达药业股份有限公司 | Kras g12d inhibitor and use in medicine |
| KR20250016234A (en) * | 2022-06-27 | 2025-02-03 | 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 | Tricyclic compounds and their uses |
| KR20250060956A (en) | 2022-08-05 | 2025-05-07 | 컴쿼트 바이오사이언시즈 인크. | Heterocyclic compounds and their uses |
| WO2024032703A1 (en) * | 2022-08-11 | 2024-02-15 | Beigene, Ltd. | Heterocyclic compounds, compositions thereof, and methods of treatment therewith |
| WO2024081674A1 (en) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Combination therapies for the treatment of cancer |
| WO2024197503A1 (en) * | 2023-03-27 | 2024-10-03 | Nikang Therapeutics , Inc. | Tricyclic derivatives as kras inhibitors |
| KR20250174948A (en) * | 2023-04-21 | 2025-12-15 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | Crystal form of nitrogen-containing tetracyclic compound and method for preparing same |
| AU2024337913A1 (en) | 2023-09-08 | 2026-03-26 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| IL327380A (en) | 2023-09-29 | 2026-05-01 | D3 Bio Wuxi Co Ltd | Combinations of wx-001 or derivatives thereof with a kras g12c inhibitor for use in the treatment of cancer |
| WO2025085748A1 (en) | 2023-10-20 | 2025-04-24 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras proteins |
| WO2025212574A1 (en) * | 2024-04-02 | 2025-10-09 | Mirati Therapeutics, Inc. | Processes for preparation of prmt5 inhibitors and intermediates for making the same |
| WO2026064527A1 (en) * | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018206539A1 (en) * | 2017-05-11 | 2018-11-15 | Astrazeneca Ab | Heteroaryl compounds that inhibit g12c mutant ras proteins |
| WO2019051291A1 (en) * | 2017-09-08 | 2019-03-14 | Amgen Inc. | KRAS G12C INHIBITORS AND METHODS OF USE |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6441910B2 (en) * | 2013-09-30 | 2018-12-19 | シャンハイ インリ ファーマシューティカル カンパニー リミティド | Fused pyrimidine compounds, intermediates, methods for their preparation, compositions and uses |
| CA3048217A1 (en) * | 2016-12-22 | 2018-06-28 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| ES2905676T3 (en) * | 2017-05-22 | 2022-04-11 | Amgen Inc | KRAS G12C inhibitors and methods for their use |
| KR102861303B1 (en) | 2017-11-15 | 2025-09-17 | 미라티 테라퓨틱스, 인크. | KRAs G12C inhibitor |
| JP7280975B2 (en) | 2019-04-28 | 2023-05-24 | ▲勁▼方医▲薬▼科技（上海）有限公司 | Oxazaquinazoline-7(8H)-ketone compound, its preparation method and its pharmaceutical use |
| CN112390818B (en) * | 2019-08-12 | 2023-08-22 | 劲方医药科技(上海)有限公司 | Substituted heteroaromatic ring dihydropyrimidinone derivatives, its preparation method and medical application |
-
2020
- 2020-08-03 CA CA3149403A patent/CA3149403A1/en active Pending
- 2020-08-03 KR KR1020227006959A patent/KR20220079521A/en not_active Ceased
- 2020-08-03 CN CN202010769535.0A patent/CN112300195B/en active Active
- 2020-08-03 WO PCT/CN2020/106573 patent/WO2021023154A1/en not_active Ceased
- 2020-08-03 AU AU2020325477A patent/AU2020325477A1/en active Pending
- 2020-08-03 US US17/632,167 patent/US20220298174A1/en active Pending
- 2020-08-03 IL IL290276A patent/IL290276B2/en unknown
- 2020-08-03 JP JP2022506075A patent/JP7756069B6/en active Active
- 2020-08-03 MX MX2022001421A patent/MX2022001421A/en unknown
- 2020-08-03 EP EP20850862.2A patent/EP4011886A4/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018206539A1 (en) * | 2017-05-11 | 2018-11-15 | Astrazeneca Ab | Heteroaryl compounds that inhibit g12c mutant ras proteins |
| WO2019051291A1 (en) * | 2017-09-08 | 2019-03-14 | Amgen Inc. | KRAS G12C INHIBITORS AND METHODS OF USE |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022543767A (en) | 2022-10-14 |
| CN112300195A (en) | 2021-02-02 |
| EP4011886A1 (en) | 2022-06-15 |
| WO2021023154A1 (en) | 2021-02-11 |
| EP4011886A4 (en) | 2023-07-26 |
| IL290276A (en) | 2022-04-01 |
| CA3149403A1 (en) | 2021-02-11 |
| AU2020325477A1 (en) | 2022-03-17 |
| JP7756069B2 (en) | 2025-10-17 |
| US20220298174A1 (en) | 2022-09-22 |
| JP7756069B6 (en) | 2025-11-27 |
| CN112300195B (en) | 2021-12-24 |
| MX2022001421A (en) | 2022-06-08 |
| IL290276B1 (en) | 2026-01-01 |
| KR20220079521A (en) | 2022-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL290276A (en) | Tetracyclic compounds, method for its preparation and use | |
| IL291467B1 (en) | Fused pyridone compound, and preparation method therefor and use thereof | |
| ZA202001447B (en) | M-diamide compound and preparation method therefor and use thereof | |
| LT4516357T (en) | Antitumor, compound, and preparation method therefor and use thereof | |
| ZA202204100B (en) | Pyridine oxynitride, preparation method therefor and use thereof | |
| SG11202106706TA (en) | Heterocyclic compound intermediate, preparation method therefor and application thereof | |
| IL285302A (en) | Compounds, compositions and methods | |
| SG11202007740TA (en) | Pyrimidine-fused cyclic compound, preparation method therefor and application thereof | |
| SG11202008132UA (en) | Composition, method and use | |
| IL289416A (en) | Tricyclic compound, preparation method therefor and use thereof | |
| IL286642A (en) | Compositions, devices and methods for factor vii therapy | |
| IL272446A (en) | Substituted penta- fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof | |
| EP3699179A4 (en) | Pyrazolyl-containing tricyclic derivative, preparation method therefor and use thereof | |
| SG11202007554TA (en) | Dioxazoline compound, preparation method therefor, and uses thereof | |
| ZA201906848B (en) | Novel pyrrolopyridine derivative, method for producing same, and use thereof | |
| EP4082534A4 (en) | Solid preparation, and preparation method therefor and use thereof | |
| PT4410788T (en) | Cyano compound, and preparation method therefor and use thereof | |
| SG11202008531RA (en) | Oxazino-quinazoline and Oxazino-quinoline Type Compound, Preparation Method and Uses Thereof | |
| SG11202103953TA (en) | Organophosphorus compound, and preparation process and use thereof | |
| IL282817A (en) | Novel compound, preparation method and application thereof | |
| IL287120A (en) | Compounds, compositions and methods | |
| EP3842438A4 (en) | Preparation method for ecteinascidin compound and intermediate thereof | |
| EP3904367A4 (en) | Tetrapeptide compound, preparation method and use thereof | |
| ZA202107832B (en) | Pyrrole amidopyridone compound, preparation method therefor and use thereof | |
| PL3750893T3 (en) | Dioxazoline compound, preparation method therefor, and uses thereof |